29.11.2017 • NewsElaine BurridgeChinaInnovation

AstraZeneca Forms Chinese JV

© AstraZeneca
© AstraZeneca

AstraZeneca has formed a joint venture with China’s Future Industry Investment Fund (FIIF) to accelerate local development of innovative medicines for patients in China and around the world.

Both partners own an equal share in the standalone company, called Dizal Pharmaceutical. Xiaolin Zhang, previously head of AstraZeneca’s Innovation Center China (ICC), has been appointed as Dizal’s CEO.

Dizal, which incorporates all scientific and technical capabilities of the ICC, holds exclusive rights to three potential medicines from the Anglo-Swedish group’s pipeline that are currently in preclinical development. The jv is also expected to initiate its own novel clinical programs.

FIFF, which is managed by SDIC Fund, a private equity company focused on investment in China, will contribute funds and expertise in establishing strategic partnerships in the country.

SDIC Fund chairman, Guohua Gao, said the synergy created by combining AstraZeneca’s scientific talent and assets with FIIF’s China expertise and funding will help further promote innovation in medical science.

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.